Kavya Rakhra

Learn More
Doxorubicin (DOX) is a member of the anthracycline class of chemotherapeutic agents used for the treatment of many common human cancers including aggressive non-Hodgkin's lymphoma [1, 2]. However, DOX is highly toxic in humans resulting in severe suppression of hematopoiesis, gastrointestinal toxicity [3] , and cardiac toxicity [4]. To date, several(More)
The dependence on the overexpression of a single oncogene constitutes an exploitable weakness for molecular targeted therapy. These drugs can produce dramatic tumor regression by targeting the driving oncogene, but relapse often follows. Understanding the complex interactions of the tumor's multifaceted response to oncogene inactivation is key to tumor(More)
  • 1